We are excited to announce that Concr has been selected to present at the prestigious 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The symposium, also known as the "triple meeting," will take place October 23-25, 2024 in Barcelona, Spain. This recognition highlights our team's dedication to advancing precision oncology using predictive analytics.
Our co-founder Dr Uzma Asghar will deliver the presentation, titled "Transforming cancer care and therapeutic development by predicting individual patient responses to treatment". It will highlight the latest validation of Concr’s FarrSight®-Twin technology, which is used to create composite “digital twins” constructed from the clinical and molecular profiles of hundreds of patients to optimise treatment choice and create more advanced synthetic controls for early clinical trials. We are honoured to have the opportunity to share our latest findings with the scientific community and engage in meaningful discussions that could shape the future of precision oncology.
Being chosen to present at ENA-2024 underscores the impact of our work and our commitment to pushing the boundaries of innovation. We look forward to connecting with fellow researchers, clinicians, and industry leaders at the conference.
Stay tuned for more updates as we prepare to showcase our research at this important event or get in touch to schedule a meeting today.
Presentation details
Title: “Transforming cancer care and therapeutic development by predicting individual patient responses to treatment”
Presenter: Dr Uzma S. Asghar (Co-founder and Chief Scientific Officer)
Session: Novel discoveries in drug development
Date: Friday 25 October
Time: 15:00-16:30 CEST
Room: 111 + 112
Event details
36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Location: International Convention Centre (CCIB), Barcelona, Spain
Dates: 23-25 October 2024
Back